Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy

Gerd Bönner, C. Balparda, C. Cuneo, C. Rojas, H. Jure, H. Luquez, O. Montaña, O. Salomone, P. Rodenas, D. Aizenberg, L. Lecocq, M. Saint-Lannes, P. Guerin, P. Jourde, M. Frohn, D. Richter, P. Leyendecker, T. Cantin, D. Smila, L. AimG. Combet, G. Bertrand, G. Lalanne, H. G. Dammann, E. Radermacher, H. J. Strotmann, K. C. Muenter, W. Daut, J. Chevts, G. Krause, K. Andreas, M. Hanefeld, A. Naumburger, O. Maus, A. Fiesselmann, R. Cama, D. Karnad, M. Thomas, S. Vidyasagar, R. Pedrinelli, M. Perticone, A. Mezzetti, S. Bosi, M. Di Biase, M. Mayer, M. Volpe, M. Uguccioni, S. Di Somma, M. Santonastaso, P. Rossi, N. Glorioso, M. Destro, L. Mos, G. Licata, V. Donadon, F. Locatelli, A. Vinciguerra, L. Sechi, G. Aucello, C. Gazzaruso, A. Bryce, G. Bustamante, W. Cabrera, J. Espinoza, J. Heredia, M. Horna, J. Parra, L. Toce, L. Watanabe, V. Kostenko, D. Butko, A. Svistov, S. Shoustov, O. Ershova, A. Konrady, S. Churina, Y. Yspenskiy, A. Petrov, E. Espinel-Garuz, J. Pau, C. Fluixa, J. Calabuig, Y. Sipan, L. Comino, J. Puig, L. Mengual, J. Perez, E. Vinyoles

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Aim. To evaluate the efficacy and tolerability of candesartan cilexetil 32 mg in combination with hydrochlorothiazide (HCT) 12.5 mg or 25 mg in hypertensive patients not optimally controlled with candesartan monotherapy. Patients and methods. A total of 3521 patients with treated or untreated hypertension and sitting diastolic blood pressure (DBP) 90-114 mmHg, entered a single-blind run-in phase with candesartan (16 mg for 2 weeks, followed by 32 mg for 6 weeks). At the end of the run-in phase, 1975 patients who still had DBP 90-114 mmHg were randomized to 8 weeks' double-blind treatment with either candesartan 32 mg (n=654), or candesartan-HCT 32/12.5 mg (n=656), or candesartan-HCT 32/25 mg (n=665). Principal results. At randomization, the mean blood pressure was similar in the three treatment groups (approximately 153/97 mmHg). It was reduced during the double-blind treatment phase by 6.1/5.6 mmHg in the candesartan 32 mg group, by 13.0/8.8 mmHg in the candesartan-HCT 32/12.5 mg group, and by 15.5/10.0 mmHg in the candesartan-HCT 32/25 mg group (p < 0.01 for all between treatment comparisons). All study treatments were generally well tolerated. Conclusion. Candesartan-HCT 32/12.5 mg and candesartan-HCT 32/25 mg are highly effective and provide improved blood pressure reduction and blood pressure control relative to candesartan 32 mg monotherapy, with maintained tolerability, in hypertensive patients whose blood pressure is not optimally controlled with candesartan monotherapy. Furthermore, candesartan-HCT 32/25 mg is more effective than candesartan-HCT 32/12.5 mg in this population.

Original languageEnglish
Pages (from-to)22-30
Number of pages9
JournalBlood Pressure
Volume17
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 30-12-2008

Fingerprint

Hydrochlorothiazide
Antihypertensive Agents
Blood Pressure
candesartan
Therapeutics
Random Allocation

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Bönner, Gerd ; Balparda, C. ; Cuneo, C. ; Rojas, C. ; Jure, H. ; Luquez, H. ; Montaña, O. ; Salomone, O. ; Rodenas, P. ; Aizenberg, D. ; Lecocq, L. ; Saint-Lannes, M. ; Guerin, P. ; Jourde, P. ; Frohn, M. ; Richter, D. ; Leyendecker, P. ; Cantin, T. ; Smila, D. ; Aim, L. ; Combet, G. ; Bertrand, G. ; Lalanne, G. ; Dammann, H. G. ; Radermacher, E. ; Strotmann, H. J. ; Muenter, K. C. ; Daut, W. ; Chevts, J. ; Krause, G. ; Andreas, K. ; Hanefeld, M. ; Naumburger, A. ; Maus, O. ; Fiesselmann, A. ; Cama, R. ; Karnad, D. ; Thomas, M. ; Vidyasagar, S. ; Pedrinelli, R. ; Perticone, M. ; Mezzetti, A. ; Bosi, S. ; Di Biase, M. ; Mayer, M. ; Volpe, M. ; Uguccioni, M. ; Di Somma, S. ; Santonastaso, M. ; Rossi, P. ; Glorioso, N. ; Destro, M. ; Mos, L. ; Licata, G. ; Donadon, V. ; Locatelli, F. ; Vinciguerra, A. ; Sechi, L. ; Aucello, G. ; Gazzaruso, C. ; Bryce, A. ; Bustamante, G. ; Cabrera, W. ; Espinoza, J. ; Heredia, J. ; Horna, M. ; Parra, J. ; Toce, L. ; Watanabe, L. ; Kostenko, V. ; Butko, D. ; Svistov, A. ; Shoustov, S. ; Ershova, O. ; Konrady, A. ; Churina, S. ; Yspenskiy, Y. ; Petrov, A. ; Espinel-Garuz, E. ; Pau, J. ; Fluixa, C. ; Calabuig, J. ; Sipan, Y. ; Comino, L. ; Puig, J. ; Mengual, L. ; Perez, J. ; Vinyoles, E. / Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. In: Blood Pressure. 2008 ; Vol. 17, No. SUPPL. 2. pp. 22-30.
@article{f447cbf445fa477d982f3f9781edb39e,
title = "Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy",
abstract = "Aim. To evaluate the efficacy and tolerability of candesartan cilexetil 32 mg in combination with hydrochlorothiazide (HCT) 12.5 mg or 25 mg in hypertensive patients not optimally controlled with candesartan monotherapy. Patients and methods. A total of 3521 patients with treated or untreated hypertension and sitting diastolic blood pressure (DBP) 90-114 mmHg, entered a single-blind run-in phase with candesartan (16 mg for 2 weeks, followed by 32 mg for 6 weeks). At the end of the run-in phase, 1975 patients who still had DBP 90-114 mmHg were randomized to 8 weeks' double-blind treatment with either candesartan 32 mg (n=654), or candesartan-HCT 32/12.5 mg (n=656), or candesartan-HCT 32/25 mg (n=665). Principal results. At randomization, the mean blood pressure was similar in the three treatment groups (approximately 153/97 mmHg). It was reduced during the double-blind treatment phase by 6.1/5.6 mmHg in the candesartan 32 mg group, by 13.0/8.8 mmHg in the candesartan-HCT 32/12.5 mg group, and by 15.5/10.0 mmHg in the candesartan-HCT 32/25 mg group (p < 0.01 for all between treatment comparisons). All study treatments were generally well tolerated. Conclusion. Candesartan-HCT 32/12.5 mg and candesartan-HCT 32/25 mg are highly effective and provide improved blood pressure reduction and blood pressure control relative to candesartan 32 mg monotherapy, with maintained tolerability, in hypertensive patients whose blood pressure is not optimally controlled with candesartan monotherapy. Furthermore, candesartan-HCT 32/25 mg is more effective than candesartan-HCT 32/12.5 mg in this population.",
author = "Gerd B{\"o}nner and C. Balparda and C. Cuneo and C. Rojas and H. Jure and H. Luquez and O. Monta{\~n}a and O. Salomone and P. Rodenas and D. Aizenberg and L. Lecocq and M. Saint-Lannes and P. Guerin and P. Jourde and M. Frohn and D. Richter and P. Leyendecker and T. Cantin and D. Smila and L. Aim and G. Combet and G. Bertrand and G. Lalanne and Dammann, {H. G.} and E. Radermacher and Strotmann, {H. J.} and Muenter, {K. C.} and W. Daut and J. Chevts and G. Krause and K. Andreas and M. Hanefeld and A. Naumburger and O. Maus and A. Fiesselmann and R. Cama and D. Karnad and M. Thomas and S. Vidyasagar and R. Pedrinelli and M. Perticone and A. Mezzetti and S. Bosi and {Di Biase}, M. and M. Mayer and M. Volpe and M. Uguccioni and {Di Somma}, S. and M. Santonastaso and P. Rossi and N. Glorioso and M. Destro and L. Mos and G. Licata and V. Donadon and F. Locatelli and A. Vinciguerra and L. Sechi and G. Aucello and C. Gazzaruso and A. Bryce and G. Bustamante and W. Cabrera and J. Espinoza and J. Heredia and M. Horna and J. Parra and L. Toce and L. Watanabe and V. Kostenko and D. Butko and A. Svistov and S. Shoustov and O. Ershova and A. Konrady and S. Churina and Y. Yspenskiy and A. Petrov and E. Espinel-Garuz and J. Pau and C. Fluixa and J. Calabuig and Y. Sipan and L. Comino and J. Puig and L. Mengual and J. Perez and E. Vinyoles",
year = "2008",
month = "12",
day = "30",
doi = "10.1080/08038020802519220",
language = "English",
volume = "17",
pages = "22--30",
journal = "Blood Pressure",
issn = "0803-7051",
publisher = "Informa Healthcare",
number = "SUPPL. 2",

}

Bönner, G, Balparda, C, Cuneo, C, Rojas, C, Jure, H, Luquez, H, Montaña, O, Salomone, O, Rodenas, P, Aizenberg, D, Lecocq, L, Saint-Lannes, M, Guerin, P, Jourde, P, Frohn, M, Richter, D, Leyendecker, P, Cantin, T, Smila, D, Aim, L, Combet, G, Bertrand, G, Lalanne, G, Dammann, HG, Radermacher, E, Strotmann, HJ, Muenter, KC, Daut, W, Chevts, J, Krause, G, Andreas, K, Hanefeld, M, Naumburger, A, Maus, O, Fiesselmann, A, Cama, R, Karnad, D, Thomas, M, Vidyasagar, S, Pedrinelli, R, Perticone, M, Mezzetti, A, Bosi, S, Di Biase, M, Mayer, M, Volpe, M, Uguccioni, M, Di Somma, S, Santonastaso, M, Rossi, P, Glorioso, N, Destro, M, Mos, L, Licata, G, Donadon, V, Locatelli, F, Vinciguerra, A, Sechi, L, Aucello, G, Gazzaruso, C, Bryce, A, Bustamante, G, Cabrera, W, Espinoza, J, Heredia, J, Horna, M, Parra, J, Toce, L, Watanabe, L, Kostenko, V, Butko, D, Svistov, A, Shoustov, S, Ershova, O, Konrady, A, Churina, S, Yspenskiy, Y, Petrov, A, Espinel-Garuz, E, Pau, J, Fluixa, C, Calabuig, J, Sipan, Y, Comino, L, Puig, J, Mengual, L, Perez, J & Vinyoles, E 2008, 'Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy', Blood Pressure, vol. 17, no. SUPPL. 2, pp. 22-30. https://doi.org/10.1080/08038020802519220

Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. / Bönner, Gerd; Balparda, C.; Cuneo, C.; Rojas, C.; Jure, H.; Luquez, H.; Montaña, O.; Salomone, O.; Rodenas, P.; Aizenberg, D.; Lecocq, L.; Saint-Lannes, M.; Guerin, P.; Jourde, P.; Frohn, M.; Richter, D.; Leyendecker, P.; Cantin, T.; Smila, D.; Aim, L.; Combet, G.; Bertrand, G.; Lalanne, G.; Dammann, H. G.; Radermacher, E.; Strotmann, H. J.; Muenter, K. C.; Daut, W.; Chevts, J.; Krause, G.; Andreas, K.; Hanefeld, M.; Naumburger, A.; Maus, O.; Fiesselmann, A.; Cama, R.; Karnad, D.; Thomas, M.; Vidyasagar, S.; Pedrinelli, R.; Perticone, M.; Mezzetti, A.; Bosi, S.; Di Biase, M.; Mayer, M.; Volpe, M.; Uguccioni, M.; Di Somma, S.; Santonastaso, M.; Rossi, P.; Glorioso, N.; Destro, M.; Mos, L.; Licata, G.; Donadon, V.; Locatelli, F.; Vinciguerra, A.; Sechi, L.; Aucello, G.; Gazzaruso, C.; Bryce, A.; Bustamante, G.; Cabrera, W.; Espinoza, J.; Heredia, J.; Horna, M.; Parra, J.; Toce, L.; Watanabe, L.; Kostenko, V.; Butko, D.; Svistov, A.; Shoustov, S.; Ershova, O.; Konrady, A.; Churina, S.; Yspenskiy, Y.; Petrov, A.; Espinel-Garuz, E.; Pau, J.; Fluixa, C.; Calabuig, J.; Sipan, Y.; Comino, L.; Puig, J.; Mengual, L.; Perez, J.; Vinyoles, E.

In: Blood Pressure, Vol. 17, No. SUPPL. 2, 30.12.2008, p. 22-30.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy

AU - Bönner, Gerd

AU - Balparda, C.

AU - Cuneo, C.

AU - Rojas, C.

AU - Jure, H.

AU - Luquez, H.

AU - Montaña, O.

AU - Salomone, O.

AU - Rodenas, P.

AU - Aizenberg, D.

AU - Lecocq, L.

AU - Saint-Lannes, M.

AU - Guerin, P.

AU - Jourde, P.

AU - Frohn, M.

AU - Richter, D.

AU - Leyendecker, P.

AU - Cantin, T.

AU - Smila, D.

AU - Aim, L.

AU - Combet, G.

AU - Bertrand, G.

AU - Lalanne, G.

AU - Dammann, H. G.

AU - Radermacher, E.

AU - Strotmann, H. J.

AU - Muenter, K. C.

AU - Daut, W.

AU - Chevts, J.

AU - Krause, G.

AU - Andreas, K.

AU - Hanefeld, M.

AU - Naumburger, A.

AU - Maus, O.

AU - Fiesselmann, A.

AU - Cama, R.

AU - Karnad, D.

AU - Thomas, M.

AU - Vidyasagar, S.

AU - Pedrinelli, R.

AU - Perticone, M.

AU - Mezzetti, A.

AU - Bosi, S.

AU - Di Biase, M.

AU - Mayer, M.

AU - Volpe, M.

AU - Uguccioni, M.

AU - Di Somma, S.

AU - Santonastaso, M.

AU - Rossi, P.

AU - Glorioso, N.

AU - Destro, M.

AU - Mos, L.

AU - Licata, G.

AU - Donadon, V.

AU - Locatelli, F.

AU - Vinciguerra, A.

AU - Sechi, L.

AU - Aucello, G.

AU - Gazzaruso, C.

AU - Bryce, A.

AU - Bustamante, G.

AU - Cabrera, W.

AU - Espinoza, J.

AU - Heredia, J.

AU - Horna, M.

AU - Parra, J.

AU - Toce, L.

AU - Watanabe, L.

AU - Kostenko, V.

AU - Butko, D.

AU - Svistov, A.

AU - Shoustov, S.

AU - Ershova, O.

AU - Konrady, A.

AU - Churina, S.

AU - Yspenskiy, Y.

AU - Petrov, A.

AU - Espinel-Garuz, E.

AU - Pau, J.

AU - Fluixa, C.

AU - Calabuig, J.

AU - Sipan, Y.

AU - Comino, L.

AU - Puig, J.

AU - Mengual, L.

AU - Perez, J.

AU - Vinyoles, E.

PY - 2008/12/30

Y1 - 2008/12/30

N2 - Aim. To evaluate the efficacy and tolerability of candesartan cilexetil 32 mg in combination with hydrochlorothiazide (HCT) 12.5 mg or 25 mg in hypertensive patients not optimally controlled with candesartan monotherapy. Patients and methods. A total of 3521 patients with treated or untreated hypertension and sitting diastolic blood pressure (DBP) 90-114 mmHg, entered a single-blind run-in phase with candesartan (16 mg for 2 weeks, followed by 32 mg for 6 weeks). At the end of the run-in phase, 1975 patients who still had DBP 90-114 mmHg were randomized to 8 weeks' double-blind treatment with either candesartan 32 mg (n=654), or candesartan-HCT 32/12.5 mg (n=656), or candesartan-HCT 32/25 mg (n=665). Principal results. At randomization, the mean blood pressure was similar in the three treatment groups (approximately 153/97 mmHg). It was reduced during the double-blind treatment phase by 6.1/5.6 mmHg in the candesartan 32 mg group, by 13.0/8.8 mmHg in the candesartan-HCT 32/12.5 mg group, and by 15.5/10.0 mmHg in the candesartan-HCT 32/25 mg group (p < 0.01 for all between treatment comparisons). All study treatments were generally well tolerated. Conclusion. Candesartan-HCT 32/12.5 mg and candesartan-HCT 32/25 mg are highly effective and provide improved blood pressure reduction and blood pressure control relative to candesartan 32 mg monotherapy, with maintained tolerability, in hypertensive patients whose blood pressure is not optimally controlled with candesartan monotherapy. Furthermore, candesartan-HCT 32/25 mg is more effective than candesartan-HCT 32/12.5 mg in this population.

AB - Aim. To evaluate the efficacy and tolerability of candesartan cilexetil 32 mg in combination with hydrochlorothiazide (HCT) 12.5 mg or 25 mg in hypertensive patients not optimally controlled with candesartan monotherapy. Patients and methods. A total of 3521 patients with treated or untreated hypertension and sitting diastolic blood pressure (DBP) 90-114 mmHg, entered a single-blind run-in phase with candesartan (16 mg for 2 weeks, followed by 32 mg for 6 weeks). At the end of the run-in phase, 1975 patients who still had DBP 90-114 mmHg were randomized to 8 weeks' double-blind treatment with either candesartan 32 mg (n=654), or candesartan-HCT 32/12.5 mg (n=656), or candesartan-HCT 32/25 mg (n=665). Principal results. At randomization, the mean blood pressure was similar in the three treatment groups (approximately 153/97 mmHg). It was reduced during the double-blind treatment phase by 6.1/5.6 mmHg in the candesartan 32 mg group, by 13.0/8.8 mmHg in the candesartan-HCT 32/12.5 mg group, and by 15.5/10.0 mmHg in the candesartan-HCT 32/25 mg group (p < 0.01 for all between treatment comparisons). All study treatments were generally well tolerated. Conclusion. Candesartan-HCT 32/12.5 mg and candesartan-HCT 32/25 mg are highly effective and provide improved blood pressure reduction and blood pressure control relative to candesartan 32 mg monotherapy, with maintained tolerability, in hypertensive patients whose blood pressure is not optimally controlled with candesartan monotherapy. Furthermore, candesartan-HCT 32/25 mg is more effective than candesartan-HCT 32/12.5 mg in this population.

UR - http://www.scopus.com/inward/record.url?scp=57949116276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57949116276&partnerID=8YFLogxK

U2 - 10.1080/08038020802519220

DO - 10.1080/08038020802519220

M3 - Article

C2 - 19085342

AN - SCOPUS:57949116276

VL - 17

SP - 22

EP - 30

JO - Blood Pressure

JF - Blood Pressure

SN - 0803-7051

IS - SUPPL. 2

ER -